MVR-T7011 / ImmVira Pharma - LARVOL DELTA

“Armed” oncolytic herpes simplex virus enables CD19 CAR-T for solid tumor cell treatment as a combination therapy (AACR 2023) - "The in vivo efficacy studies demonstrated that IT and IP administration of T7011, rather than MVR-T3011 virus which lacks CD19, specifically promoted CD19 CAR-T anti-solid tumor activities in both immunodeficient and immunocompetent mice. The new-generation of HSV oncolytic virus T7011 expressing the targetable CD19 antigen on tumor surface enables the CD19 CAR-T for solid tumor cell treatment as a combination therapy. The new-generation of HSV oncolytic virus T7011 expressing the targetable CD19 antigen on tumor surface enables the CD19 CAR-T for solid tumor cell treatment as a combination therapy. In addition, T7011 also carries multi-immunomodulators further to enhance antitumor efficacy by reinvigorating the infiltrated CAR-T cells and reversing the immunosuppressive TME. T7011 is expected to be a promising combinational therapy with CD19-specific CAR-T cells enabling effective cell therapy against multiple solid tumors."

Combination therapy • IO biomarker • Tumor cell • Hematological Malignancies • Oncology • Solid Tumor • CD19 • IL12A

AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting (PRNewswire) - "At the AACR meeting, ImmVira presented the main preclinical study results of MVR-T7011 for the first time....Results from in vivo efficacy tests demonstrated that both intratumoral (IT) and intraperitoneal (IP) administration of MVR-T7011 can activate CAR-T cell proliferation, leading to synergistic antitumor effects against various solid tumors....In the future, ImmVira will start IND filing preparation once reaching strategic partnership."

Preclinical • Oncology • Solid Tumor